David Craig on Muck Rack

David Craig

New York
As seen in: USA Today, Aol, Fortune, Agenda (World Economic Forum), Flipboard, Phys.org, The Scotsman, Yahoo, Washington Times, LifeSiteNews.com and
Senior markets editor, USA TODAY
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with David

Contact David, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

What Kansas City World Cup visitors need to know about our weird weed laws | Opinion

|
By David Craig
| Kansas City Star Verified
Marijuana is legal to buy here. Can you smoke it outside? And what if you’re staying on the Kansas side of the state line? | Opinion The World Cup has generated exactly the excitement Kansas City has been building toward for four years. Hotels are busy. Restaurants are staffed. The hospitality infrastructure has been assembled with a global audience in mind.
Open in Who Shared Issue with article?

The dangers of raising speed limits on interstates

|
By David Craig
| Yahoo Verified
65 mph speed limit sign with a background of long exposure trails. - Wirestock Creators // Shutterstock The dangers of raising speed limits on interstates The recent increase in the speed limit on I-465 in Indiana, from 55 mph to 65 mph, raises the question of whether raising the speed limit on highways is a good idea. While the increase is meant to enhance the flow of traffic on the often busy interstate, there are several potential dangers that drivers may not consider.
Open in Who Shared View Duplicates (70) Issue with article?

David Craig

|
By David Craig
| BioSpace Verified
David Craig is CEO of Sarcomatrix Therapeutics, a biotechnology company developing small molecule therapies for muscle diseases. He previously held executive roles at Amgen, Gilead and Alexion, and advocates for pragmatic, multi-modal innovation in rare disease drug development.
Open in Who Shared Issue with article?
See all 205 licensed articles (210 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified